Biotech
Appears in 1 story
Subsidiary of Eli Lilly; VERVE-102 in Phase 1b clinical trials targeting PCSK9
For two decades, lowering LDL cholesterol meant statins—daily pills that work for most but leave roughly one in five patients with muscle pain or liver enzyme changes severe enough to quit. On May 1, researchers at the University of Barcelona and Oregon Health & Science University published results on a short, engineered DNA molecule that silences the gene controlling how the liver clears LDL, cutting cholesterol by nearly 50 percent in mice after a single injection.
Updated May 7
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
